Farah Cassis-Ghavami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Farah Cassis-Ghavami has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Amalia S. Magaret
University of Washington, Seattle, WA, United States
1 shared publication - Ann Duerr
Vaccine and Infectious Diseases Institute, Fred Hutchinson Cancer Research Center, Seattle
1 shared publication - Connie Celum
Departments of Global Health, Medicine, and Epidemiology, University of Washington, Seattle, WA
1 shared publication - Gregory A. Spies1 shared publication
- Jorge Sanchez
Asociación Civil Impacta Salud y Educación, Lima, Peru
1 shared publication - Joseph B. Margolick
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health , Baltimore, Maryland
1 shared publication
Latest Publications
- 14 January 2011
- Published by Wolters Kluwer Health in AIDS
- Vol. 25 (2) , 153-158
Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case–control study
Adenoviruses are among the most promising vectors for the development of an HIV vaccine. The results of the phase IIB study of the adenovirus serotype 5-based Merck Trivalent HIV vaccine have raised the concern that serological immunity to adenovirus serotype 5 (Ad5) could be linked to HIV acquisition risk in high-risk individuals. We examined the association between adenovirus serostatus and the rate of incident HIV infection in populations at elevated risk of HIV acquisition. We performed a nested case–control study of Ad5 serostatus among 299 HIV-infected and 590 matched HIV-uninfected persons participating in the Multicenter AIDS Cohort Study (MACS) and in HPTN 039, a study of herpes simplex virus 2 suppression among adults in the United States, South America, and Africa. Appropriate HIV cases and controls were identified in each cohort, and Ad5-neutralizing antibody titers were compared in these two groups. In MACS and HPTN 039, the relative risks of incident HIV infection among Ad5-seropositive vs. Ad5-seronegative individuals were 1.1 (95% confidence interval 0.8–1.5, P = 0.57) and 1.0 (95% confidence interval 0.4–2.3, P = 0.99), respectively. HIV-1 acquisition rates did not vary significantly by Ad5-neutralizing antibody titer. The presence of Ad5-neutralizing antibodies is not linked to the risk of HIV acquisition among populations at elevated risk of HIV infection.
- 14 January 2011
- Published by Wolters Kluwer Health in AIDS
- Vol. 25 (2) , 153-158
Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case–control study
Adenoviruses are among the most promising vectors for the development of an HIV vaccine. The results of the phase IIB study of the adenovirus serotype 5-based Merck Trivalent HIV vaccine have raised the concern that serological immunity to adenovirus serotype 5 (Ad5) could be linked to HIV acquisition risk in high-risk individuals. We examined the association between adenovirus serostatus and the rate of incident HIV infection in populations at elevated risk of HIV acquisition. We performed a nested case–control study of Ad5 serostatus among 299 HIV-infected and 590 matched HIV-uninfected persons participating in the Multicenter AIDS Cohort Study (MACS) and in HPTN 039, a study of herpes simplex virus 2 suppression among adults in the United States, South America, and Africa. Appropriate HIV cases and controls were identified in each cohort, and Ad5-neutralizing antibody titers were compared in these two groups. In MACS and HPTN 039, the relative risks of incident HIV infection among Ad5-seropositive vs. Ad5-seronegative individuals were 1.1 (95% confidence interval 0.8–1.5, P = 0.57) and 1.0 (95% confidence interval 0.4–2.3, P = 0.99), respectively. HIV-1 acquisition rates did not vary significantly by Ad5-neutralizing antibody titer. The presence of Ad5-neutralizing antibodies is not linked to the risk of HIV acquisition among populations at elevated risk of HIV infection.